🧾 What This Document Is

This is a Definitive Proxy Statement (DEF 14A) for Ionis Pharmaceuticals. It’s essentially the official "playbook" and ballot for the company's 2026 Annual Meeting of Stockholders. Its job is to inform you, the shareholder, about what will be voted on and provide the details you need to make informed decisions. Think of it as an invitation to a virtual meeting along with the agenda and background reading.

👉 In simple terms: This document tells you when the meeting is, what you're voting on, and why the board recommends each vote.

🏢 What The Company Does

Ionis Pharmaceuticals is a biotechnology company focused on discovering and developing RNA-targeted medicines. Their technology platform is designed to treat serious diseases by editing the instructions (RNA) that cause them. They are a fully integrated company, meaning they handle everything from early research to commercializing their own drugs.

👉 Why it matters: As a pioneer in a complex, cutting-edge field, the company's success heavily depends on attracting and retaining top scientific talent and having strong, knowledgeable oversight from its Board of Directors.

🗳️ The Meeting & Voting Logistics

• Date & Time: June 4, 2026, at 2:00 p.m. Pacific Time.
• Format: Virtual only. You can attend, listen, ask questions, and vote online at www.virtualshareholdermeeting.com/IONS2026.
• Record Date: April 7, 2026. Only shareholders on this date can vote.
• Quorum Needed: At least 50% of outstanding shares must be represented for the meeting to be valid.
• How to Vote: You can vote online, by phone, or by mail before the meeting. If you attend the virtual meeting, you can also vote live. If your shares are held by a broker (in "street name"), you must get a proxy from them to vote at the meeting.

📋 What You're Voting On (The Proposals)

The board recommends a "FOR" vote on all five items.

Proposal	What It Is	Why It Matters
1. Election of Directors	Vote to re-elect Spencer R. Berthelsen and Joan E. Herman to the board for a 3-year term.	Ensures continuity and expertise on the board. Two long-serving directors (B. Lynne Parshall and Joseph H. Wender) are stepping down.
2. Advisory Vote on Executive Pay ("Say-on-Pay")	A non-binding vote to approve the compensation of the company's top executives.	Gives shareholders a voice on whether the pay packages for the CEO and other leaders are fair and aligned with company performance.
3. Amend 2011 Equity Incentive Plan	Approve adding 9.5 million more shares to the plan, bringing the total to 52 million shares.	The company says it's running low on shares to grant as stock options and awards. This is crucial for hiring and retaining the scientists and staff needed to compete.
4. Amend Employee Stock Purchase Plan (ESPP)	Approve adding 750,000 more shares and removing the plan's end date.	Allows employees to continue buying company stock at a discount, which is a common benefit to align employee and shareholder interests.
5. Ratify Auditors	Approve the selection of Ernst & Young LLP as the independent auditing firm for 2026.	A routine but important check to ensure the company's financial statements are examined by a trusted, external firm.

🏛️ Board & Governance Highlights

• Classified Board: Directors serve staggered 3-year terms, which the board believes provides stability as they execute their commercial strategy.
• Committee Structure: The board has six specialized committees (Audit, Compensation, Nominating, Medical & Science, Finance, Compliance) to provide deep oversight.
• Director Skills: The board matrix shows a mix of expertise in biotech commercialization, medical/science, and finance/corporate governance.
• Independence: All members of the key Audit, Compensation, and Nominating committees are independent directors with no ties to the company.
• Risk Oversight: The board has a formal process to oversee major risks, from financial and cybersecurity to clinical development and compliance.

💼 Executive Compensation Philosophy

The compensation program is designed to pay for performance and align executives with long-term shareholder success. Key practices include:

• High Performance-Based Pay: ~60% of the CEO's 2025 compensation was performance-based (bonuses, stock options, PRSUs).
• Increased Performance Shares: Starting in 2026, 40% of executives' equity will be in Performance Stock Units (PSUs), up from previous levels.
• Strong Guardrails: No "gross-up" payments, no hedging/pledging of stock, a clawback policy, and strict stock ownership guidelines for leaders.

⚖️ Big Picture: Strengths & Risks

👍 Strengths:

• Innovative Platform: A leader in a powerful and evolving technology (RNA-targeted medicines).
• Integrated Model: Combines research, development, and commercial capabilities.
• Governance: Structured board oversight and compensation plans designed to drive long-term value.

⚠️ Risks & Considerations:

• Competitive Talent Market: The need to constantly approve more equity shares highlights the fierce competition for skilled employees in biotech.
• Execution Risk: Successfully launching and growing commercial drugs is critical to funding future R&D.
• Pipeline Risk: Like all drug companies, its future depends on the success of clinical trials and regulatory approvals.

🧠 The Analogy

This proxy statement is like the rulebook and playbook for a critical team sport season. The "team" is Ionis Pharmaceuticals. The "coaches and strategists" are the Board of Directors, and you, the shareholder, are the team's owners. The document lets you:

1. Vote on the coaching staff (Proposal 1: Elect Directors).
2. Approve the players' contracts to keep the team competitive (Proposals 3 & 4: Equity Plans).
3. Audit the scoreboard to ensure fair play (Proposal 5: Auditors).
4. Give feedback on the performance incentives for the team captains (Proposal 2: Say-on-Pay).

🧩 Final Takeaway

This is a routine but crucial annual governance filing. The most consequential asks are for shareholders to approve a significant increase in the equity pool (Proposal 3) to retain talent and to renew the board's expertise (Proposal 1). The board's recommendations are unanimous, signaling confidence in their strategic direction.